A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury

Summary

Hospital acquired acute kidney injury is an important negative outcome predictor for hospitalized patients. Uremic toxins accumulated after a given renal insult. Some of these uremic toxins are protein bound and may accumulated after renal impairment, owing to both impaired filtration, and inflammation. Recent animal studies have reported that accumulation of uremic toxins, namely indoxyl sulfate and p-cresol, would down regulate endothelial progenitor cells and in turn affect renal recovery. Elimination of these protein bound uremic toxins with an activated charcoal would help restore endothelial function. We will conduct a double blinded randomized placebo controlled trial, which aims to determine that if oral activated charcoal will retard progression of AKI. Also, a panel of markers for endothelial function will also be determined.

Conditions

• Acute Kidney Injury

Interventions

DRUG

AST-120and pentoxyphylline (PTX)

AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.

DRUG

pentoxyphylline (PTX)

pentoxyphylline 400mg QD PO x 10 days.

Sponsors & Collaborators

• National Taiwan University Hospital, Yun-Lin Branch

  collaborator OTHER

• National Taiwan University Hospital Hsin-Chu Branch

  collaborator OTHER

• China Medical University Hospital

  collaborator OTHER

• Taoyuan General Hospital

  collaborator OTHER_GOV

• Taipei Medical University Hospital

  collaborator OTHER

• Chang Gung Memorial Hospital

  collaborator OTHER

• National Taiwan University Hospital

  lead OTHER

Principal Investigators

• YU-SHENG WU · National Taiwan University Hospital

• Tao-Min Huang · National Taiwan University Hospital, Yun-Lin Branch

• Wei-Shun Yang · National Taiwan University Hospital Hsin-Chu Branch

• JUI-HSIANG LIN · Taoyuan General Hospital

• Ya-Fei Yang · China Medical University Hospital

• Chan-Yu Lin · Chang Gung Memorial Hospital

• Heng-Chih Pan · Chang Gung Memorial Hospital

• Chih-Chin Kao · Taipei Medical University Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

100 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-01-31

Primary Completion

2017-12-31

Completion

2017-12-31

Countries

• Taiwan

Study Locations